Figure 2.

Combining pharmacological ascorbate and PARPis synergistically inhibits the viability of BRCA1/2 wild-type EOC cells. Cell viability of (A) SHIN3 (5 independent experiments each performed in triplicate) or (B) OVCAR cells (4 independent experiments each performed in triplicate) following treatment with vehicle, 2.5 mM ascorbate, 20 µM olaparib, 20 µM veliparib, ascorbate + olaparib or ascorbate + veliparib for 24 and 48 h. Data are expressed as the mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001 vs. control; ^#P<0.05, ^##P<0.01, ^###P<0.001 vs. Asc; ^$P<0.05, ^$$P<0.01 vs. olaparib; ^@P<0.05, ^@@P<0.01 vs. veliparib. EOC, epithelial ovarian cancer; PARPi, poly(ADP-ribose) polymerase inhibitor; Asc, pharmacological ascorbate.